U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot

Reuters11-13 15:03

Nov 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMN Healthcare Services, Chart Industries and Home Depot, on Wednesday.

HIGHLIGHTS

* AMN Healthcare Services Inc : Jefferies cuts target price to $27

from $41

* Bristol-Myers Squibb Co : JP Morgan raises target price to $70

from $64

* Chart Industries Inc : HSBC raises target price to $205 from

$190

* Home Depot Inc : Wedbush raises target price to $440 from $410

* Nuvalent Inc : Jefferies raises target price to $137 from $97

Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.

* Americold Realty Trust Inc : RBC cuts target price to $30 from $33

* AMN Healthcare Services Inc : Jefferies cuts target price to $27 from $41

* Atlanticus Holdings Corp : KBW raises target price to $45 from $33

* Axsome Therapeutics Inc : Leerink Partners raises PT to $110 from $100

* Axsome Therapeutics Inc : Piper Sandler raises PT to $117 from $115

* Axsome Therapeutics Inc : RBC raises target price to $132 from $131

* Biohaven Ltd : RBC cuts target price to $66 from $68

* Biohaven Ltd : TD Cowen raises target price to $75 from $55

* Biolife Solutions Inc : Jefferies raises target price to $30 from $26

* Biolife Solutions Inc : TD Cowen raises target price to $31 from $28

* Bridgebio pharma Inc : Raymond James raises target price to $48 from $46

* Bristol-Myers Squibb Co : JP Morgan raises target price to $70 from $64

* Cava Group Inc : Stifel raises target price to $175 from $118

* Chart Industries Inc : HSBC raises target price to $205 from $190

* Dayforce Inc : Barclays raises target price to $80 from $70

* Dayforce Inc : JP Morgan raises target price to $73 from $63

* Dime Community Bancshares Inc : KBW raises target price to $38 from $35

* Dime Community Bancshares Inc : Raymond James raises PT to $42 from $36

* Echostar Corp : TD Cowen cuts target price to $30 from $37

* Edgewise Therapeutics Inc : JP Morgan raises target price to $42 from

$36

* Edgewise Therapeutics Inc : Leerink Partners raises PT to $44 from $42

* Evercommerce Inc : RBC raises target price to $14 from $12

* Fate Therapeutics Inc : Jefferies cuts target price to $10 from $12

* Heron Therapeutics Inc : Needham cuts target price to $4 from $5

* Home Depot Inc : HSBC raises target price to $356 from $318

* Home Depot Inc : Wedbush raises target price to $440 from $410

* Honeywell : RBC raises target price to $253 from $213

* IAC Inc : Oppenheimer cuts target price to $72 from $75

* ICU Medical Inc : Jefferies raises target price to $200 from $183

* Indaptus Therapeutics Inc : Maxim Group cuts target price to $5 from $8

* Installed Building Products Inc : Jefferies cuts PT to $235 from $252

* Iteos Therapeutics Inc : JP Morgan cuts target price to $22 from $24

* Kezar Life Sciences Inc : Jefferies cuts target price to $18 from $30

* Legend Biotech Corp : Piper Sandler cuts target price to $78 from $90

* Light & Wonder Inc : Jefferies cuts target price to $120 from $122

* Lineage Inc : RBC cuts target price to $81 from $94

* Maplebear Inc : Wedbush raises target price to $48 from $38

* Mosaic Co : CIBC cuts target price to $30 from $32

* Neuronetics Inc : Piper Sandler cuts target price to $2 from $4

* Novavax Inc : TD Cowen cuts target price to $9 from $14

* Nuvalent Inc : Jefferies raises target price to $137 from $97

* Pactiv Evergreen Inc : RBC raises target price to $14 from $13

* Palisade Bio Inc : Maxim Group cuts target price to $8 from $22.50

* Perspective Therapeutics Inc : RBC cuts target price to $25 from $27

* Prime Medicine Inc : Chardan Capital Markets cuts PT to $15 from $17

* Pubmatic Inc : RBC raises target price to $21 from $20

* Quanterix Corp : TD Cowen raises target price to $16 from $13.50

* Repay Holdings Corp : D.A. Davidson cuts target price to $14 from $16

* Rocket Companies Inc : Jefferies cuts target price to $15 from $17.50

* Rocket Companies Inc : RBC cuts target price to $18 from $20

* Runway Growth Finance Corp : JP Morgan cuts target price to $10.50 from

$11

* Sangamo Therapeutics Inc : Jefferies cuts target price to $7 from $8

* Scholar Rock Holding Corp : H.C. Wainwright raises PT to $40 from $35

* Scholar Rock Holding Corp : Raymond James raises target price to $39

from $30

* Shift4 Payments Inc : KBW raises target price to $112 from $105

* Shift4 Payments Inc : Raymond James raises target price to $115 from $84

* Shift4 Payments Inc : Stephens raises target price to $120 from $110

* Shift4 Payments Inc : Susquehanna raises target price to $120 from $105

* Shoals Technologies Group Inc : JP Morgan cuts target price to $11 from

$12

* Shoals Technologies Group Inc : TD Cowen raises PT to $11 from $9.50

* Shopify Inc : CIBC raises target price to $135 from $85

* Shopify Inc : JP Morgan raises target price to $121 from $76

* Shopify Inc : RBC raises target price to $130 from $100

* Si-Bone Inc : Jefferies cuts target price to $25 from $28

* Skyworks Solutions Inc : JP Morgan cuts target price to $100 from $120

* Theriva Biologics Inc : Maxim Group cuts target price to $6 from $25

* Tyson Foods Inc : Piper Sandler raises target price to $58 from $50

* Walker & Dunlop Inc : KBW raises target price to $120 from 117

* Williams Companies Inc : RBC raises target price to $60 from $56

* Zoominfo Technologies Inc : D.A. Davidson raises PT to $13 from $9.50

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment